RT Journal Article
SR Electronic
T1 Persistence of robust humoral immune response in COVID-19 convalescent individuals over 12 months after infection
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.09.27.21264013
DO 10.1101/2021.09.27.21264013
A1 Miyakawa, Kei
A1 Kubo, Sousuke
A1 Jeremiah, Sundararaj Stanleyraj
A1 Go, Hirofumi
A1 Yamaoka, Yutaro
A1 Ohtake, Norihisa
A1 Kato, Hideaki
A1 Ikeda, Satoshi
A1 Mihara, Takahiro
A1 Matsuba, Ikuro
A1 Sanno, Naoko
A1 Miyakawa, Masaaki
A1 Shinkai, Masaharu
A1 Miyazaki, Tomoyuki
A1 Ogura, Takashi
A1 Ito, Shuichi
A1 Kaneko, Takeshi
A1 Yamamoto, Kouji
A1 Goto, Atsushi
A1 Ryo, Akihide
YR 2021
UL http://medrxiv.org/content/early/2021/09/29/2021.09.27.21264013.abstract
AB SARS-CoV-2 infection elicits varying degrees of protective immunity conferred by neutralizing antibodies (nAbs). Here we report the persistence of nAb responses over 12 months after infection despite its decreasing trend noticed from 6 months. The study included sera from 358 individuals who had been infected with SARS-CoV-2 between January and May 2020. Samples were collected at 6 and 12 months after onset. The titers of IgG to the viral nucleocapsid protein (NP) and receptor-binding domain of the spike protein (RBD) were measured by CLEIA. The nAb titer was determined using lentivirus-based pseudovirus or authentic virus. Antibody titers of NP-IgG, RBD-IgG, and nAbs were higher in severe and moderate cases than in mild cases at 12 months after onset. While the nAb levels were likely to confer adequate protection against wild-type viral infection, the neutralization activity to recently circulating variants in some of the mild cases (∼30%) was undermined, implying the susceptibility of reinfection to the variants of concerns (VOCs). COVID-19 convalescent individuals have robust humoral immunity even at 12 months after infection albeit that the medical history and background of patients could affect the function and dynamics of antibody response to the VOCs.Competing Interest StatementYY is a current employee of Kanto Chemical Co., Inc, and NO is a current employee of Tosoh Corporation. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.Funding StatementThis research was supported by AMED under grant numbers JP19fk0108110 and JP20he0522001.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All participants provided written informed consent and the study was approved by the Institutional Review Board of Yokohama City University (Reference No. B200600115, B200700023, B210300001).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets presented in this article are not readily available because it is difficult to ensure the de-identification of data. However, they can be available from the corresponding authors on reasonable request.